Medical Devices; Hematology and Pathology Devices; Classification of the Digital Cervical Cytology Slide Imaging System With Artificial Intelligence Algorithm
Key claim: The FDA is classifying digital cervical cytology slide imaging systems equipped with artificial intelligence algorithms as Class II medical devices, establishing regulatory special controls that enable future similar diagnostic tools to seek clearance via the streamlined 510(k) pathway.
Abstract
(Rule · Health and Human Services Department, Food and Drug Administration) The Food and Drug Administration (FDA) is classifying the digital cervical cytology slide imaging system with artificial intelligence algorithm into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the digital cervical cytology slide imaging system with artificial intelligence algorithm. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients’ access to beneficial innovative devices, in part by reducing regulatory burdens.
Why this matters
The final rule adds a binding, application-specific framework for medical AI rather than general obligations for AI developers or platforms. Developers of similar cervical cytology imaging systems gain a 510(k) route subject to substantial equivalence and applicable controls, while clinical users should distinguish establishment of this device category from clearance of any future product.